Dicerna Pharmaceuticals Gets $4M More In Series B Round’s Second Close
Dicerna Pharmaceuticals Inc. held a second close of its Series B financing round with $4 million more. The Watertown, Mass-based drug developer has raised a total of $29 million in the round. GlaxoSmithKline’s corporate healthcare venture capital arm (SR One) is a new investor. Dicerna’s existing investors include Oxford Bioscience Partners, Skyline Ventures, Abingworth and Domain Associates. Brian M. Gallagher, a partner at SR One, will join Dicerna’s board.
22 October 2010•4 mins read
